Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Filed with BSE · · 2 pages · English
Summary by 6ix AI
The certificate confirms that all shares of the company are held in dematerialized form and no requests for dematerialization were received during the quarter. This filing serves to inform the BSE about the compliance status regarding shareholding.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Sub: Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2026. Sir / Ma’am, We hereby enclose a certificate under regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2026 received from M/s. Bigshare Services Private Limited, Registrar and Share Transfer Agent of our c
Goldline Pharmaceutical Ltd. on 6ix
Earlier from Goldline Pharmaceutical
- Goldline Pharmaceutical Ltd. Press Release Jul 14 2026
- Announcement under Regulation 30 (LODR)-Change in Management
- Goldline Pharmaceutical Ltd. Press Release Jun 24 2026
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
- Goldline Pharmaceutical Ltd. Press Release Jun 09 2026
Later from Goldline Pharmaceutical
- Goldline Pharmaceutical Ltd. Press Release Jul 30 2026
- Announcement under Regulation 30 (LODR)-Newspaper Publication
- Goldline Pharmaceutical Ltd. Press Release Aug 07 2026
- Goldline Pharmaceutical Ltd. Press Release Aug 29 2026
- Shareholder Meeting / Postal Ballot-Outcome of AGM
Follow Goldline Pharmaceutical into a list and get an email when it puts out news.
Follow Goldline Pharmaceutical